These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 15767024)

  • 1. Clinical heterogeneity of drug hypersensitivity.
    Roujeau JC
    Toxicology; 2005 Apr; 209(2):123-9. PubMed ID: 15767024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy.
    Mockenhaupt M
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):142-60; quiz 161-2. PubMed ID: 19371237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
    Wolf R; Matz H; Marcos B; Orion E
    Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
    Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
    Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.
    Walsh SA; Creamer D
    Clin Exp Dermatol; 2011 Jan; 36(1):6-11. PubMed ID: 21143513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
    Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
    Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
    Ding WY; Lee CK; Choon SE
    Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.
    Ghislain PD; Roujeau JC
    Dermatol Online J; 2002 Jun; 8(1):5. PubMed ID: 12165215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype standardization for immune-mediated drug-induced skin injury.
    Pirmohamed M; Friedmann PS; Molokhia M; Loke YK; Smith C; Phillips E; La Grenade L; Carleton B; Papaluca-Amati M; Demoly P; Shear NH
    Clin Pharmacol Ther; 2011 Jun; 89(6):896-901. PubMed ID: 21562486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valdecoxib-associated acute generalized exanthematous pustulosis.
    Byerly FL; Nelson KC; Granko RP; Morrell DS; Cairns BA
    Burns; 2005 May; 31(3):383-7. PubMed ID: 15774300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of cutaneous adverse drug reactions.
    Mockenhaupt M
    Chem Immunol Allergy; 2012; 97():1-17. PubMed ID: 22613850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
    Paulmann M; Mockenhaupt M
    Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug reaction with eosinophilia and systemic symptoms].
    Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
    Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
    Mustafa SS; Ostrov D; Yerly D
    Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).
    Sidoroff A; Dunant A; Viboud C; Halevy S; Bavinck JN; Naldi L; Mockenhaupt M; Fagot JP; Roujeau JC
    Br J Dermatol; 2007 Nov; 157(5):989-96. PubMed ID: 17854366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cutaneous reactions to drugs].
    Mulder WM; Meinardi MM; Bruynzeel DP
    Ned Tijdschr Geneeskd; 2004 Feb; 148(9):415-20. PubMed ID: 15038200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DRESS syndrome with mild manifestations as a diagnostic and therapeutic problem: case report.
    Artuković M; Kustelega J; Lugović-Mihić L
    Acta Clin Croat; 2010 Dec; 49(4):479-84. PubMed ID: 21830461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition and management of severe cutaneous drug reactions.
    Knowles SR; Shear NH
    Dermatol Clin; 2007 Apr; 25(2):245-53, viii. PubMed ID: 17430761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Life-threatening acute adverse cutaneous drug reactions.
    Wolf R; Orion E; Marcos B; Matz H
    Clin Dermatol; 2005; 23(2):171-81. PubMed ID: 15802211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective.
    Todd G
    Dermatol Clin; 2006 Oct; 24(4):459-72, vi. PubMed ID: 17010776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.